Loading organizations...
§ Private Profile · Boston, MA, USA
Biopharma company developing biosimilar monoclonal antibodies & therapeutic proteins for autoimmune & rare diseases.
Epirus Biopharmaceuticals has raised $36.0M across 1 funding round.
Epirus Biopharmaceuticals has raised $36.0M in total across 1 funding round.
Epirus Biopharmaceuticals was a Boston, Massachusetts-based biotechnology company that developed biosimilar monoclonal antibodies and therapeutic proteins targeting autoimmune conditions and rare diseases. The enterprise pursued a global commercialization strategy through regional partnerships, advancing a clinical pipeline that featured biosimilar equivalents to major biologic drugs like Remicade, Soliris, and Actemra. To fund these development efforts, Epirus secured substantial venture capital, highlighted by a $36 million Series B financing round in 2013 led by Livzon Mabpharm, alongside institutional backers TPG Biotech, 5AM Ventures, and Montreux Equity Partners. Following an all-stock merger with Zalicus, the corporate entity scaled to a peak headcount of 73 employees by March 2015, though subsequent financial constraints forced a 40 percent workforce reduction and a strategic pipeline pivot. Epirus Biopharmaceuticals was founded in 2011 by founding chief executive officer Amit Munshi.
Epirus Biopharmaceuticals has raised $36.0M in total across 1 funding round.
Epirus Biopharmaceuticals's investors include Daotian Fu, 5AM Ventures, Adage Capital Management, Gibralt US, Greenwoods Investment, Monashee Investment Management, Montreux Equity Partners, Mousse Partners, TPG Biotech.
Epirus Biopharmaceuticals has raised $36.0M across 1 funding round. Most recently, it raised $36.0M Series B in April 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 16, 2014 | $36M Series B | Daotian FU | 5AM Ventures, Adage Capital Management, Gibralt US, Greenwoods Investment, Monashee Investment Management, Montreux Equity Partners, Mousse Partners, TPG Biotech | Announced |